11609<\/a>.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
}
, "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
, "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:25:32.523Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Home Care Services: Living Wage"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what discussions he has had with home social care providers on the effect of the national living wage on the financial position of those providers; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/177", "label" : {"_value" : "Biography information for Gareth Thomas"}
}
, "tablingMemberConstituency" : {"_value" : "Harrow West"}
, "tablingMemberPrinted" : [{"_value" : "Gareth Thomas"}
], "uin" : "13500"}
, {"_about" : "http://data.parliament.uk/resources/423864", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423864/answer", "answerText" : {"_value" : "
Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.<\/p>
Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.<\/p>
In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn\u2019s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.<\/p>
In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.<\/p>
NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn\u2019s diseases and ulcerative colitis in its guidance Crohn\u2019s Disease Management in Adults, Children and Young People<\/em> in October 2012, and Ulcerative Colitis<\/em> Management in Adults, Children and Young People<\/em> , published in June 2013. Treatment for both Crohn\u2019s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "13299"}
, {"_value" : "13300"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:23:06.45Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Crohn's Disease"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what progress has been made on tackling Crohn's disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4519", "label" : {"_value" : "Biography information for James Cartlidge"}
}
, "tablingMemberConstituency" : {"_value" : "South Suffolk"}
, "tablingMemberPrinted" : [{"_value" : "James Cartlidge"}
], "uin" : "13375"}
, {"_about" : "http://data.parliament.uk/resources/423943", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423943/answer", "answerText" : {"_value" : "
Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.<\/p>
Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.<\/p>
In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn\u2019s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.<\/p>
In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.<\/p>
NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn\u2019s diseases and ulcerative colitis in its guidance Crohn\u2019s Disease Management in Adults, Children and Young People<\/em> in October 2012, and Ulcerative Colitis<\/em> Management in Adults, Children and Young People<\/em> , published in June 2013. Treatment for both Crohn\u2019s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "13300"}
, {"_value" : "13375"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:23:06.353Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Inflammatory Bowel Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what estimate his Department has made of the number of people with both ulcerative colitis and Crohn's disease who have benefitted from the use of vedolizumab as a treatment option since February 2015; and what the cost of this treatment has been in that period.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3939", "label" : {"_value" : "Biography information for Andrew Percy"}
}
, "tablingMemberConstituency" : {"_value" : "Brigg and Goole"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Percy"}
], "uin" : "13299"}
, {"_about" : "http://data.parliament.uk/resources/423944", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423944/answer", "answerText" : {"_value" : "
Information is not collected centrally on the number of people prescribed medicines or the medical condition being treated.<\/p>
Some data is available for the administration of vedolizumab however this data does not correspond to patient numbers nor can it be linked to the treatment of specific diseases. Some information on cost is also available but this is the cost of the medicines at NHS list price and not necessarily the price that hospitals paid.<\/p>
In guidance published in August 2015, the National Institute for Health and Care Excellence (NICE) advised that vedolizumab is the recommended treatment for adults with moderate to severe Crohn\u2019s disease if a type of treatment called a tumour necrosis factor alpha inhibitor is not suitable or has not worked well enough. NICE also recommend vedolizumab as a possible treatment for adults with moderate to severe ulcerative colitis in separate guidance published on 5 June 2015.<\/p>
In both cases, people should be able to have vedolizumab until it stops working, or surgery is needed, or for 12 months after starting it, whichever is shorter. Their condition should be assessed 12 months after they started taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have the drug. If they no longer have symptoms, treatment can be stopped, and later restarted if their symptoms return. Drugs recommended by NICE should be available on the NHS within three months of the technology appraisal guidance being issued.<\/p>
NICE has set out best practice in the diagnosis, treatment care and support of patients with Crohn\u2019s diseases and ulcerative colitis in its guidance Crohn\u2019s Disease Management in Adults, Children and Young People<\/em> in October 2012, and Ulcerative Colitis<\/em> Management in Adults, Children and Young People<\/em> , published in June 2013. Treatment for both Crohn\u2019s disease and ulcerative colitis is largely directed at symptom relief to improve quality of life, rather than cure. Management options include drug therapy, dietary and lifestyle advice and, in severe or chronic active disease, surgery.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : [{"_value" : "13299"}
, {"_value" : "13375"}
], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:23:06.403Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Crohn's Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment his Department has made of the effectiveness of vedolizumab as a treatment for Crohn's disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/3939", "label" : {"_value" : "Biography information for Andrew Percy"}
}
, "tablingMemberConstituency" : {"_value" : "Brigg and Goole"}
, "tablingMemberPrinted" : [{"_value" : "Andrew Percy"}
], "uin" : "13300"}
, {"_about" : "http://data.parliament.uk/resources/423952", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423952/answer", "answerText" : {"_value" : "The National Institute for Health and Care Excellence (NICE) is the independent body which makes decisions on the clinical and cost effectiveness of products based on a thorough assessment of the best available evidence and in consultation with stakeholders. National Health Service commissioners are required to fund drugs and treatments recommended by NICE technology appraisals.<\/p>
Bendamustine (Levact) is recommended by NICE as a possible treatment for some people with chronic lymphocytic leukaemia of Binet stage B or C.<\/p>
NICE is currently appraising ibrutinib (Imbruvica) for the treatment of (i) chronic lymphocytic leukaemia (NICE\u2019s final guidance is expected in June 2016) and (ii) mantle cell, relapsed, refractory lymphoma (NICE\u2019s final guidance is expected in December 2016).<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"}
}
, "answeringMemberConstituency" : {"_value" : "Mid Norfolk"}
, "answeringMemberPrinted" : {"_value" : "George Freeman"}
, "dateOfAnswer" : {"_value" : "2015-10-29", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-29T17:31:39.653Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-26", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cancer: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what recent assessment he has made of the effectiveness of the (a) Bendamustine and (b) Ibrutinib drugs in treating cancer; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/253", "label" : {"_value" : "Biography information for Mr Laurence Robertson"}
}
, "tablingMemberConstituency" : {"_value" : "Tewkesbury"}
, "tablingMemberPrinted" : [{"_value" : "Mr Laurence Robertson"}
], "uin" : "13444"}
, {"_about" : "http://data.parliament.uk/resources/423565", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423565/answer", "answerText" : {"_value" : "
A number of operational standards related to access and waiting times have been introduced or amended since May 2010. All the changes were based on recommendations from clinical experts.<\/p>
As part of our response to the Independent Cancer Taskforce\u2019s report, we have announced our commitment that \u2013 by 2020 \u2013 95% of National Health Service patients will be given a definitive cancer diagnosis or the all clear within 28 days of being referred by a general practitioner. This will be underpinned by investment - expected to be £300 million more in diagnostics a year by 2020.<\/p>
<\/strong><\/p>We are also introducing the first waiting times standards specifically for mental health so that, from April 2016:<\/p>
- 75% of people will be referred to the Improving Access to Psychological Therapies programme within six weeks, with 95% of people being referred within 18 weeks; and<\/p>
- 50% of people experiencing a first episode of psychosis will be treated within two weeks.<\/p>
"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/3918", "label" : {"_value" : "Biography information for Jane Ellison"}
}
, "answeringMemberConstituency" : {"_value" : "Battersea"}
, "answeringMemberPrinted" : {"_value" : "Jane Ellison"}
, "dateOfAnswer" : {"_value" : "2015-10-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-28T17:29:53.433Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS Trusts: Standards"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, what new performance target for Trusts and Foundation Trusts has been introduced since May 2010; and which new performance targets he plans to introduce for those bodies over the next five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4418", "label" : {"_value" : "Biography information for Justin Madders"}
}
, "tablingMemberConstituency" : {"_value" : "Ellesmere Port and Neston"}
, "tablingMemberPrinted" : [{"_value" : "Justin Madders"}
], "uin" : "13250"}
, {"_about" : "http://data.parliament.uk/resources/423566", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423566/answer", "answerText" : {"_value" : "
The Government has protected the funding the National Health Service receives and increased the Department\u2019s budget in real terms year on year. There is no plan to change this, fulfilling the Government\u2019s manifesto commitment. By 2020-21, the Government will increase funding for the NHS by £10 billion a year in real terms compared to 2014-15 to support the implementation of the NHS\u2019s own plan - the NHS Five Year Forward View - to transform services across the country.<\/p>
<\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
}
, "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
, "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
, "dateOfAnswer" : {"_value" : "2015-10-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-28T17:01:45.723Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Department of Health: Public Expenditure"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, if he will make it his policy to maintain ringfencing for total NHS funding in the Autumn Statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4418", "label" : {"_value" : "Biography information for Justin Madders"}
}
, "tablingMemberConstituency" : {"_value" : "Ellesmere Port and Neston"}
, "tablingMemberPrinted" : [{"_value" : "Justin Madders"}
], "uin" : "13249"}
, {"_about" : "http://data.parliament.uk/resources/423570", "AnsweringBody" : [{"_value" : "Department of Health"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/423570/answer", "answerText" : {"_value" : "There were 756 training places commissioned for improving access to psychological therapies (IAPT) programmes in 2014/15. In addition 509 trainees attended Child and Young People\u2019s (CYP) IAPT courses in 2014/15.<\/p>
The following table contains an aggregate of the number of training places that have been commissioned in each of the last four financial years for the IAPT programmes. Comparable information relating to the IAPT programmes is not held centrally for the 2011/12 financial year.<\/p>
2012/13<\/p><\/td> | 2013/14<\/p><\/td> | 2014/15<\/p><\/td> | 2015/16<\/p><\/td><\/tr> |
IAPT training places commissioned<\/p><\/td> | 634<\/p><\/td> | 859<\/p><\/td> | 756<\/p><\/td> | 946<\/p><\/td><\/tr><\/tbody><\/table> Source: <\/em>multi professional education and training budget monitoring returns<\/p>
The following table details the number of trainees attending CYP IAPT courses per year of the programme in the last five years.<\/p>
<\/p><\/td>
| 2011/12<\/p><\/td> | 2012/13<\/p><\/td> | 2013/14<\/p><\/td> | 2014/15<\/p><\/td> | 2015/16<\/p><\/td><\/tr> | Trainee Therapist<\/p><\/td> | 97<\/p><\/td> | 142<\/p><\/td> | 252<\/p><\/td> | 372<\/p><\/td> | 537<\/p><\/td><\/tr> | Supervisor
<\/p><\/td> | 30<\/p><\/td> | 45<\/p><\/td> | 88<\/p><\/td> | 86<\/p><\/td> | 113<\/p><\/td><\/tr> | Service Lead<\/p><\/td> | 35<\/p><\/td> | 48<\/p><\/td> | 73<\/p><\/td> | 51<\/p><\/td> | 114<\/p><\/td><\/tr> | TOTAL
<\/p><\/td> | 162<\/p><\/td> | 235<\/p><\/td> | 413<\/p><\/td> | 509<\/p><\/td> | 764<\/p><\/td><\/tr><\/tbody><\/table> Source: <\/em>NHS England<\/p><\/strong><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/1201", "label" : {"_value" : "Biography information for Alistair Burt"}
}
, "answeringMemberConstituency" : {"_value" : "North East Bedfordshire"}
, "answeringMemberPrinted" : {"_value" : "Alistair Burt"}
, "dateOfAnswer" : {"_value" : "2015-10-28", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "13216"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2015-10-28T17:03:52.56Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health"}
, "answeringDeptSortName" : {"_value" : "Health"}
, "date" : {"_value" : "2015-10-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mental Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health, how many training places in the Improving Access to Psychological Therapies service there were in each of the last five years.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4036", "label" : {"_value" : "Biography information for Luciana Berger"}
}
, "tablingMemberConstituency" : {"_value" : "Liverpool, Wavertree"}
, "tablingMemberPrinted" : [{"_value" : "Luciana Berger"}
], "uin" : "13214"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-answer.dateOfAnswer=2015-10-22&_page=1&answeringDeptId=17&max-answer.dateOfAnswer=2015-10-29&max-answer.questionFirstAnswered.=2018-11-12T15%3A35%3A43.347Z", "page" : 0, "startIndex" : 1, "totalResults" : 223, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}
|
|